Giuseppe Cimino - Publications

Long-term therapy with elexacaftor/tezacaftor/ivacaftor improves cystic fibrosis lung disease and monocyte function.

Journal: Respiratory medicine

Published: November 08, 2025

Long-term impact of Elexacaftor/Tezacaftor/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: A real-world cohort study.

Journal: British journal of clinical pharmacology

Published: October 14, 2025

Real-World Safety and Effectiveness of Elexacaftor, Tezacaftor, and Ivacaftor in People with Cystic Fibrosis and Advanced Lung Disease: A Two-Year Multicenter Cohort Study.

Journal: International journal of molecular sciences

Published: October 10, 2025

CFTR Modulator Response in Nasal Organoids Derived from People with Cystic Fibrosis.

Journal: Cells

Published: October 02, 2025

Short-term monitoring of CFTR modulator therapy in adults and children with cystic fibrosis using low and ultra-low-dose lung CT.

Journal: La Radiologia medica

Published: August 16, 2025

Dupixent's Efficacy in Cystic Fibrosis Related Chronic Rhinosinusitis With Nasal Polyposis: A Pilot Study.

Journal: Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery

Published: July 11, 2025

Real-World Evaluation of Outcomes and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Pediatric Patients With Cystic Fibrosis: A Retrospective Study.

Journal: Clinical and translational science

Published: May 04, 2025

Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.

Journal: Leukemia

Published: March 04, 2025

A family cluster of persistent Pandoraea vervacti infection in cystic fibrosis.

Journal: Journal of immunoassay & immunochemistry

Published: February 12, 2025

Elexacaftor/tezacaftor/ivacaftor (ETI) therapy modifies the expression of interferon beta and inflammatory genes in the airways of adult patients with cystic fibrosis: a pilot study.

Journal: Molecular and cellular biochemistry

Published: January 24, 2025

Improved Clinical Outcomes With Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Lung Disease: Real-World Evidence From an Italian Single-Center Study.

Journal: Pharmacology research & perspectives

Published: December 22, 2024

Cefiderocol activity against planktonic and biofilm forms of β-lactamase-producing pseudomonas aeruginosa from people with cystic fibrosis.

Journal: Journal of global antimicrobial resistance

Published: November 08, 2024